Clinical trials: Non-hematologic Malignancies
Leukemia, Myeloid, Acute, Leukemia, B-cell
Precision Exercise in Children With Malignant Hemopathies
In the early years of life and during adolescence, physical activity is crucial for good development of motor skills. It is even more so for those children and young people who are forced to undergo anti-cancer therapies and…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T Cell, Lymphoma, Hodgkin
- Trial name
- SportTherapy (NCT04090268)
- Testing
- Sport Therapy
- Where
- Italy
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- University of Milano Bicocca
Chronic Lymphocytic Leukemia (CLL)
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Investigational Drug: Ofatumumab (Azerra) Route of Administration: Intravenous (IV) Hypothesis: This study is designed to assess the toxicity and overall response rate.
- Trial name
- NCT01125787
- Testing
- ofatumumab + bendamustine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Nevada Cancer Institute
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hematologic Neoplasm, HIV Infection
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
This study will investigate the safety and effectiveness of a new stem cell transplant procedure to treat acute or chronic leukemia, multiple myeloma, myelodysplastic syndrome, Hodgkin's and non-Hodgkin's lymphoma in HIV-infected…
- Trial name
- NCT00005785
- Testing
- GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Myeloid Leukemia
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.
NGS studies will be done in stem cell leukemic population. The analysis of the samples to the diagnosis will be carried out using the 26 consensus genes: ASXL1 had, CBL, CEBPA, DNMT3A, EZH2, FLT3, GATA2, IDH1, IDH2, JAK2, KIT…
- Trial name
- NCT03311815
- Testing
- NGS techniques
- Where
- 7 sites in Spain
- Volunteers
- 900 people
- Sponsor
- PETHEMA Foundation
Anemia
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Comparing two drugs to treat subjects with non-myeloid malignancies receiving multicycle chemotherapy.
- Trial name
- NCT00148421
- Testing
- Darbepoetin alfa and Epoetin alfa
- Sponsor
- Amgen
Lymphoma
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, and radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab…
- Trial name
- NCT00334438
- Testing
- rituximab, bortezomib, yttrium Y 90 ibritumomab tiuxetan
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, Mantle-Cell
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by…
- Trial name
- BRUIN-MCL-321 (NCT04662255)
- Testing
- Pirtobrutinib, Ibrutinib, Acalabrutinib
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 500 people
- Sponsor
- Loxo Oncology, Inc.
Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL).
- Conditions
- Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma, Primary Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- VISMOLY (NCT01944943)
- Testing
- Vismodegib
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- The Lymphoma Academic Research Organisation
Acute Myeloid Leukaemia
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S64315 with azacitidine in patients with acute myeloid leukaemia.
- Trial name
- NCT04629443
- Testing
- S 64315 (also referred as MIK665) and azacitidine
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 17 people
- Sponsor
- Institut de Recherches Internationales Servier
Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies.
- Trial name
- NCT01090414
- Testing
- Idelalisib
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences
Polycythemia Vera
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
Jakavi® therapy for polycythemia vera (PV) has so far been studied exclusively in clinical trials and at selected clinical trial centres.
- Trial name
- PAVE (NCT05853445)
- Testing
- Jakavi
- Where
- 99 sites in Germany
- Volunteers
- 467 people
- Sponsor
- Novartis Pharmaceuticals
Bladder Cancer, Cervical Cancer
Zinc Supplements in Lowering Cadmium Levels in Smokers
RATIONALE: Zinc supplements may lower cadmium levels in smokers and may help prevent DNA damage. PURPOSE: This clinical trial is studying how well zinc supplements work in lowering cadmium levels in smokers.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00376987
- Testing
- zinc oxide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia, Myelodysplasia
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days <30%. A TRM of >50% is considered unacceptable.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00513175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Acute Myelogenous Leukemia, B-cell Lymphoma
FT516 in Subjects With Advanced Hematologic Malignancies
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma.
- Trial name
- NCT04023071
- Testing
- FT516, Rituximab, Obinutuzumab
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Fate Therapeutics
Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available.
- Trial name
- NCT03374332
- Testing
- Gemtuzumab Ozogamicin (GO), Donor Leukocytes
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Leukemia, Lymphoma
Study of @neWorld: A Virtual Community for Children With Cancer
RATIONALE: Using an Internet Web site that enables children with cancer to interact online with classmates, participate in classroom activities, get easy-to-read medical information, and chat with family members, medical staff…
- Conditions
- Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00070421
- Testing
- complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Sponsor
- Leap of Faith Technologies
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00612716
- Testing
- busulfan, cyclophosphamide, Stem cell infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
The aim of this non-interventional study is to collect primarily the percentage of patients who receive the full dose of dexamethasone (20 or 40 mg orally once daily on days 1, 8, 15 and 22 of the repetitive 28-day cycles, 20 mg…
- Trial name
- NCT03001804
- Where
- 12 sites in Austria
- Volunteers
- 29 people
- Sponsor
- Celgene
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
This phase I trial studies the side effects and best dose of the anti-OX40 antibody BMS-986178 when given together with the TLR9 agonist SD-101 and radiation therapy in treating patients with low-grade B-cell Non-Hodgkin…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT03410901
- Testing
- Anti-OX40 Antibody BMS 986178, Laboratory Biomarker Analysis, Radiation Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Ronald Levy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.